BioCorRx Business Update for the First Quarter of 2022
BioCorRx Inc. (BICX) announced significant advancements in its first quarter of 2022, including the initiation of a clinical trial for BICX104, a biodegradable naltrexone pellet aimed at treating opioid use disorder.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCorRx Inc. (BICX) announced significant advancements in its first quarter of 2022, including the initiation of a clinical trial for BICX104, a biodegradable naltrexone pellet aimed at treating opioid use disorder. The recruitment for this Phase 1 study is a critical milestone. Additionally, the company reported a revenue increase due to a higher patient count in licensed clinics and growing participation in its UnCraveRx™ Weight Loss Management Program. Operating expenses were reduced by nearly 30%, showcasing effective cost management.
Positive
- Initiation of BICX104 clinical trial for opioid use disorder.
- Increased revenue driven by higher patient numbers at licensed clinics.
- Growth in UnCraveRx™ program enrollment.
- Operating expenses decreased by nearly 30%.
Negative
- None.
Details
News Market Reaction – BICX
The recorded move for BICX in the trading session of this news was -15.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANAHEIM, CA, May 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the first quarter ended March 31, 2022 and reported on recent corporate developments.
Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., commented, “We are pleased to report progress on our upcoming first-in-human clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled R&D subsidiary.”
“Last month, we announced that we have begun the recruiting and enrollment process for the clinical trial. This was a major milestone as it marks the next phase of development for BICX104. The BICX104 clinical study is a Phase 1, open-label, single-center study in two parallel groups of randomized healthy volunteers to evaluate the pharmacokinetics and safety of BICX104 implantable subcutaneous naltrexone pellets and the marketed once a month intramuscular depot naltrexone injection. We are in the recruiting phase and look forward to providing progress updates as they become available.”
“Additionally, we saw an increase in revenue in the first quarter of 2022 due to the increased number of patients treated at licensed clinics. Furthermore, we were pleased to see that membership/program fees also increased for the first quarter of 2022 due to more customers signing up for our UnCraveRx™ Weight Loss Management Program.
At the same time, we continue to carefully manage expenses and reduced operating expenses by nearly
BICX104 is being developed in collaboration with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under RFA DA-19-002,
“Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional).” The Company has an active Investigational New Drug (IND) status, and the FDA has deemed the 505(b)(2) abbreviated pathway acceptable, as well the opportunity to seek eventual dual indication on the product for OUD and Alcohol Use Disorder (AUD).
A copy of the Company’s annual report on Form 10-Q for the first quarter ended March 31, 2022 has been filed with the Securities and Exchange Commission and posted on the Company’s website at https://ir.biocorrx.com/.
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts and personal support from behavioral experts; please visit www.uncraverx.com for more information on UnCraveRx®. The Company also controls BioCorRx Pharmaceuticals, a clinical stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone pellet for treatment of alcohol and opioid use disorders. For more information on BICX and its subsidiary pipeline, please visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown. risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
212- 671-1020 x304
bicx@crescendo-ir.com
Media Contact
PhillComm Global
BioCorRx@PhillComm.Global
704-942-1557
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.